Financial Data and Key Metrics Changes - In 2025, the company achieved a revenue growth of approximately 4% to $2.1 billion, marking the highest combined full-year revenue [9] - Adjusted EBITDA for the full year was approximately $312 million, with an adjusted EBITDA margin of 14.8% [9][24] - For Q4 2025, total revenue was $508 million, reflecting a flat year-over-year performance, with adjusted gross profit increasing by 8% to $197 million [22][24] Business Line Data and Key Metrics Changes - In the Inspection and Mitigation (I&M) segment, revenue was approximately $1.1 billion for 2025, remaining roughly flat year-over-year, with an adjusted gross margin of 27.8% [19][20] - The Consulting Engineering (CE) segment saw revenue of $714 million, up roughly 8% against 2024, with an adjusted gross margin of 47.0% [20][21] - Geospatial (Geo) revenue was $298 million, up roughly 6% against 2024, with an adjusted gross margin of 51.5% [21] Market Data and Key Metrics Changes - The backlog within CE and Geo was $1.07 billion, up about 10% from approximately $970 million last year [15] - Data center revenue increased significantly, reaching nearly $70 million in 2025, more than doubling from the prior year [12] - The federal funding lapse affected timing of work in Geo but did not lead to material cancellations [14] Company Strategy and Development Direction - The company plans to accelerate organic growth with a focus on cross-selling and deeper client engagement across segments [10] - There is a strong emphasis on strengthening organizational alignment and cultural cohesion while driving margin expansion through cost management [10][16] - The company aims to leverage its combined capabilities to expand share of wallet with key clients in infrastructure, industrial, utilities, and government sectors [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the leadership transition and the strategic direction of the company, highlighting the importance of maintaining operational stability during the transition [7][31] - The company anticipates continued growth driven by infrastructure reinvestment and regulatory compliance, with a focus on execution and delivering on targets [34] - For 2026, the company expects revenue in the range of $2.15 billion to $2.25 billion, with adjusted EBITDA between $330 million and $355 million [27] Other Important Information - The company completed a $250 million private placement to strengthen its balance sheet and provide flexibility for growth opportunities [25] - An integration program is underway, with a commitment to deliver $25 million in cost synergies, with half expected to be realized in 2026 [26] - A $200 million share repurchase program has been authorized to provide flexibility based on market conditions [32] Q&A Session Summary Question: Can you talk more about the integration process and specific milestones for 2026? - Management expressed confidence in the integration process, focusing on communication, culture, and achieving cost savings [39] Question: What are the biggest potential synergies and go-to-market strategies? - Management highlighted exciting developments in cross-selling opportunities, particularly in the data center space [40][41] Question: What are the expectations for the energy and oil end markets? - Management indicated good visibility on planned outages and run-and-maintain contracts, suggesting stability in the energy sector [51] Question: Can you elaborate on the EBITDA margins in the latest 2026 guidance? - Management acknowledged adjustments due to stock compensation changes but emphasized growth and margin expansion from improved execution [59] Question: How does the current situation in the Middle East impact the business? - Management noted that the Middle East represents a small portion of the business, with minimal current impact from rising oil prices [65] Question: What is the outlook for capital allocation? - Management confirmed a robust tuck-in acquisition pipeline while maintaining flexibility for share buybacks based on market conditions [78][79]

Financial Data and Key Metrics Changes - Net sales increased by 17% to $779 million, driven by new store openings and comparable store sales growth [17] - Comparable store sales rose by 3.6%, supported by increases in both basket size and transaction counts [17] - Adjusted net income increased by 16% to $85 million, and adjusted earnings per share rose by 17% to $1.39 [20] - Gross margin was 39.9%, slightly below the previous year due to planned price investments [19] - Total cash and investments increased by over 31% to $563 million, with no meaningful long-term debt [21] Business Line Data and Key Metrics Changes - Seasonal, consumable, hardware, stationery, and sporting goods were the top-performing categories [18] - Membership in the Ollie's Army loyalty program grew by 23%, with total customer file increasing by over 12% [7] Market Data and Key Metrics Changes - The company opened a record 86 stores in the previous year, significantly higher than the previous record of 50 [5] - The company plans to open 75 new stores in 2026, continuing its expansion into new markets [10] Company Strategy and Development Direction - The company aims to enhance growth through new store openings and improving customer experience [10][11] - A flexible off-price buying model is being utilized to leverage growing buying power and improve merchandise assortment [8] - The company is committed to a long-term goal of over 1,300 stores, with a focus on maintaining a strong balance sheet and returning cash to shareholders [11][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a sustainable comparable store sales growth target of 2% and a gross margin target of 40.5% [12][24] - The company is well-positioned to benefit from retail consolidation, which is expected to enhance deal flow and access to products [12][65] - Management noted that consumer behavior is shifting towards seeking value, with strong performance in consumables [64] Other Important Information - The company is increasing its share repurchase program, targeting to return approximately 50% of free cash flow to investors [25][103] - Capital expenditures for the year are expected to be in the range of $103 million to $113 million, including investments in distribution centers [27] Q&A Session Summary Question: What is the thought process behind the change in comp growth target? - Management believes they are at an inflection point, with accelerated growth and better access to merchandise allowing for a sustainable 2% comp growth target [31] Question: How is sales productivity being managed with changes in assortments? - The company is focusing on providing the best values in relevant merchandise categories and is making investments in planning and allocation to drive higher space productivity [35][40] Question: What is the state of the consumer and the impact of tariffs? - Consumers are seeking value, with strong performance in trade down among upper-income cohorts, while lower-income cohorts show some weakness [64] Question: How is the real estate environment affecting new store growth? - The real estate environment remains strong, and the company is balancing new store growth with initiatives to improve in-store shopping experiences [69] Question: Can you quantify the comp growth from Ollie's Army membership versus new store growth? - The company has not historically separated this data but is focused on growing Ollie's Army through new stores [74] Question: What was the impact of straight-line rent in 2025 and expectations for 2026? - Straight-line rent expense was $5 million for the Big Lots locations in 2025, and the company is considering higher levels of share repurchases based on cash flow generation [100][101]

Financial Data and Key Metrics Changes - For Q4 fiscal 2026, consolidated revenues totaled $84.9 million, a decrease from $86.4 million in the prior year [29] - Net income for Q4 was $2.5 million, or $0.09 per diluted share, compared to a net loss of $5.4 million, or -$0.19 per diluted share in the previous year [30] - Gross margin improved to 47.8% of net revenues, up from 46.8% in the prior year, driven by lower promotional activity and cost savings [31] - SG&A expenses decreased by $10.6 million to $37.3 million, representing 43.9% of net revenues, down from 55.4% [32] - Operating income from continuing operations was $3.6 million, or 4.2% of net revenue, compared to an operating loss of $7.3 million in the prior year [33] Business Line Data and Key Metrics Changes - Direct segment revenues for Q4 were $74.5 million, a 2.6% decrease from $76.5 million in the prior year [30] - Indirect segment revenues increased by 4.9% to $10.4 million, driven by a large wholesale spring collaboration [31] - Comparable sales declined by 0.7%, showing sequential improvement throughout the fiscal year [30] Market Data and Key Metrics Changes - The company experienced a revenue decline of 1.7% overall in Q4, with indirect channel revenue growth of just under 5% [9] - The direct channel registered a revenue decline of 2.6%, but showed significant sequential improvement over the previous quarters [8] Company Strategy and Development Direction - The company is focused on Project Sunshine, which aims to reclaim brand relevance and increase market share through five strategic pillars [4][7] - The leadership transition, including the appointment of a permanent CEO, reflects confidence in the strategic direction and transformation plans [3][4] - The company plans to stabilize sales between $255 million and $270 million for FY 2027, emphasizing a focus on direct business and rebuilding wholesale channels [5][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transformation and the potential for long-term sustainable growth [12][37] - The company acknowledges the need to navigate through inventory challenges from previous management while focusing on product improvement [40] - The leadership is optimistic about the early successes in Q4 and the stabilization of the business, which positions them for future growth [27][37] Other Important Information - The company generated $17 million in operating cash flow in Q4, allowing for the payoff of its ABL facility [12] - Inventory decreased by nearly 17% year-over-year, indicating improved inventory management [34] - The company will not hold its annual outlet sale in Q1 to focus on inventory for stores and enhance customer experience [36] Q&A Session Summary Question: When should product flows and mix be where the company wants them to be? - Management indicated that about 80% of the spring/summer product mix has been influenced, with a blank slate for fall/winter products [39][40] Question: What will be the focus between stores and digital channels? - Management emphasized the importance of both digital and brick-and-mortar channels, with plans to optimize the existing store fleet and selectively open new brand stores [43][45] Question: Will more Outlet 2.0 stores open in FY 2027? - Management expressed an inclination to open a few more Outlet 2.0 stores in the fiscal year, refining the approach based on early successes [47][50]

Financial Data and Key Metrics Changes - Full year net sales were $1.41 billion, in line with guidance despite reduced marketing spend and lower traffic [8] - Adjusted EBITDA was $78 million, exceeding guidance of $70 million [8] - Pro forma adjusted EBITDA margin was approximately 9%, a 200 basis point improvement versus the prior year [39] - Gross profit margin for Q4 was 55.6%, a 430 basis point decline year-over-year, primarily due to a non-recurring inventory obsolescence charge [36] Business Line Data and Key Metrics Changes - The ComfortMode mattress launched in January saw sales 3.5 times expectations, nearly twice the sales of the three c-series beds it replaces [14] - The company is reducing its core lineup from 12 mattresses to 7, organized into three clear collections [17] - Operating expenses for the full year were $824 million, a $136 million reduction from the prior year [39] Market Data and Key Metrics Changes - Brand consideration among premium shoppers grew 10%, achieving the highest consideration in the premium category [24] - The company experienced significant increases in critical consideration drivers, including value, quality, and comfort [25] Company Strategy and Development Direction - The company is focused on executing a turnaround strategy that includes growth and cost-cutting measures [6] - A new product line is being launched to address customer needs for comfort, durability, and value [15] - The marketing strategy has been modernized to improve customer acquisition and brand strength [22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged pressures from severe weather and macroeconomic impacts affecting sales at the start of the year [11] - The company expects Q1 net sales to decline in the high teens percentage due to early-year softness, but anticipates significant improvement in Q2 [45] - Adjusted EBITDA for the full year is expected to increase in the high teens to mid-20s percentage range year-over-year [46] Other Important Information - The company has identified $50 million of additional annualized cost savings that are currently being executed [31][60] - Total liquidity at year-end was $58 million, well above the amended $30 million covenant floor [40] Q&A Session Summary Question: What were the main pain points addressed by the new product launches? - Management focused on expanding the audience to serve existing customers and attract younger demographics, emphasizing comfort, value, and durability [52] Question: What are the major sources of the $50 million of additional savings? - The savings will come from logistics, delivery, labor model resets, and corporate overhead structure adjustments [59] Question: What is the phasing for getting the new beds across the portfolio? - The new beds will be available for purchase starting March 23rd, with most stores set by mid-April [72] Question: Will the EBITDA growth reference the reported number or the pro forma number? - The growth will reference the reported adjusted EBITDA base of $78 million [75] Question: Will marketing spend trend back up in 2026? - Marketing spend will be held flat in 2026 compared to 2025, with increased spending in Q2, Q3, and Q4 [86]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated revenue of $120.5 million, representing nearly 9% year-over-year growth [7] - In Q4 2025, revenue reached $34.4 million, up nearly 22% year-over-year, indicating accelerating momentum [7] - GAAP net income for 2025 was $10.8 million, a year-over-year increase of more than 37%, with earnings per share of $0.10 [7] - Adjusted EBITDA expanded to $27.5 million with a 23% margin, up more than 14% year-over-year [8] - Free cash flow for 2025 reached approximately $20.5 million, compared to $13.2 million in 2024, representing growth of more than 500% from 2023 [8] Business Line Data and Key Metrics Changes - The company completed multiple acquisitions in 2025, including Medsphere Systems, which expanded its capabilities into the inpatient hospital market [10] - The integration of AI tools into the platform has already resulted in new customer wins under the CareCloud umbrella [11] - The company aims to penetrate newly acquired health system customers with its RCM and AI products as part of its 2026 growth strategy [12] Market Data and Key Metrics Changes - The healthcare technology market is at an inflection point, with AI adoption moving from pilot programs to production deployment [12] - The company recognizes a multi-billion-dollar addressable opportunity in the U.S. for its AI front desk assistant [12] Company Strategy and Development Direction - The company’s 2026 growth strategy focuses on leveraging its dual platform footprint in ambulatory and inpatient markets to drive organic growth and acquisition synergies [13] - Strategic acquisitions have been a cornerstone of growth, with a disciplined approach to acquiring companies at attractive valuations [14] - The company plans to remain active in M&A in 2026 and beyond, identifying complementary targets that can benefit from its AI capabilities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $128 million to $130 million for 2026, with adjusted EBITDA of $29 million to $31 million [15] - The company anticipates GAAP EPS of $0.20 to $0.23 per share, representing an increase of more than 100% over 2025 [15] - Management highlighted the importance of disciplined execution, innovation, and creating long-term value for stakeholders [35] Other Important Information - The company resumed dividends on its preferred shares at the beginning of 2025 and plans to pay double dividends on Series B preferred stock starting in 2026 [9] - The conversion of approximately 80% of Series A preferred shares into common eliminated more than $7 million in annual dividend obligations [9] Q&A Session Summary Question: Can you expand on how you're planning on monetizing AI in 2026? - Management discussed the favorable M&A environment and the strategy to integrate AI capabilities into acquired platforms, enhancing their attractiveness and market position [38][41] Question: What was behind the recent contract wins with new customers? - Management noted the expansion of the sales and marketing team and the focus on cross-selling and upselling existing customers, particularly those acquired through recent transactions [45][46] Question: How should investors think about CareCloud's exposure to AI disruption? - Management emphasized that the company operates in a niche healthcare IT space with deep industry moats, making it less vulnerable to generic AI disruptions [54][56] Question: What are the focuses for the use of excess cash flow? - Management indicated that the focus would be on acquisitions, enhancing the capital structure, and investing in AI development [73] Question: Who are the company's main competitors? - Management identified competitors in the EHR space such as eClinicalWorks and athenahealth, and noted that the AI competitive landscape is broader, with some players lacking a vertical approach [75][78]

Financial Data and Key Metrics Changes - Village Farms reported a net income from continuing operations of $21 million or $0.19 per share, a $49 million improvement compared to the prior year [5] - Adjusted EBITDA from continuing operations reached $50 million, an increase of $48 million, while cash flow from continuing operations improved to $58 million, up $44 million compared to 2024 [5][26] - The company achieved a year-over-year growth in net sales of 9%, totaling just shy of $50 million for Q4 [13][25] Business Line Data and Key Metrics Changes - Canadian cannabis sales grew by 10% year-over-year, with international export sales increasing nearly 400% [15][27] - Retail branded sales in Canada were flat compared to Q4 last year, but gross margins improved year-over-year, reaching 43% [15][28] - The Netherlands operations contributed $3.3 million in sales for Q4, with adjusted EBITDA of $700,000 [31] Market Data and Key Metrics Changes - The company maintained a top five overall market share position in Canada and held the number one position in dried flower as of the end of last month [15] - International export sales increased more than six-fold, benefiting from the company's leadership position as one of the largest EU GMP-certified cannabis operators [4] Company Strategy and Development Direction - Village Farms is focused on improving margin performance, profitability, and cash generation to enable additional growth investments [5] - The company is investing in capacity expansion projects in Canada and the Netherlands, with expectations of significant increases in production and revenue [20][23] - The transition to privatize the legacy produce business reflects confidence in the cannabis business's ability to stand on its own [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand fundamentals domestically and internationally, expecting to drive profitable growth in 2026 and beyond [19] - The company anticipates returning to sequential growth in international exports in Q1 and plans to ship to multiple new jurisdictions [19] - Management acknowledged temporary supply constraints but emphasized the underlying strength of the business [19] Other Important Information - The company ended the year with approximately $86 million in cash and completed a $3 million share repurchase during Q4 [24][34] - The ongoing share repurchase program reflects a balanced approach to capital allocation aimed at driving returns to shareholders [34] Q&A Session Summary Question: Share repurchases and capital allocation - Management indicated that share repurchases reflect confidence in cash generation and do not impact operational opportunities [40] Question: Growth in the German market - Management noted that regulatory uncertainties had caused a decline in imports but expected growth to return in Q1, with increasing demand anticipated [42][43] Question: Capacity constraints and market share aspirations - Management clarified that Canada remains the primary market, balancing international demand with commitments in Canada [49] - The company regained its number one flower share position in January and expects continued growth in 2026 [50]

Financial Data and Key Metrics Changes - Total revenues grew by 15% in Q4 2025 and by 27% for the full year, reaching EUR 376.1 million [2][25] - Operating profit for 2025 was $26 million, a significant improvement from a loss in 2024 [2][28] - Operating cash flow was $55 million in 2025, with cash position at year-end above that of 2024 [3][28] - Adjusted operating profit was EUR 36.4 million, compared to a loss of EUR 8.6 million in 2024 [28] Business Line Data and Key Metrics Changes - RUCONEST revenue grew 26% year-over-year and 9% in Q4 2025, with U.S. volume growth of 20% [3][9] - Joenja revenue increased by 29% year-over-year and 53% in Q4 2025, reaching $19.8 million globally [4][12] - Joenja annual revenues exceeded EUR 50 million for the first time, triggering a EUR 5 million sales milestone payment [25] Market Data and Key Metrics Changes - Joenja's growth was fueled by new patient acceleration in the U.S. and increased demand in international markets, including the U.K. [4][14] - The number of identified APDS patients in the U.S. increased by 40 in 2025, more than double the increase in 2024 [14] Company Strategy and Development Direction - The company aims to maintain strong financial discipline while investing in growth drivers, focusing on becoming a leading rare disease company [6][8] - RUCONEST is positioned as a cornerstone treatment for severe HAE patients, while Joenja is expected to generate a significant portion of future revenues [32][34] - The company is exploring geographic expansion and regulatory approvals for Joenja, with a focus on pediatric indications [15][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth for RUCONEST and Joenja, with expectations for 2026 revenue between EUR 405 million and EUR 425 million [6][29] - The company anticipates operating expenses to increase at a slower pace, despite higher R&D investments [30] - Management highlighted the importance of upcoming clinical data readouts as potential value inflection points [32][34] Other Important Information - The company completed the enrollment of two leniolisib phase II trials and expects top-line data readout in the second half of 2026 [7][19] - The company is committed to optimizing capital allocations to support growth and shareholder value [8][30] Q&A Session Summary Question: Joenja growth expectations from U.S. vs. international markets - Management expects around 70%-75% of Joenja's growth in 2026 to come from the U.S. market [41][43] Question: RUCONEST patient return dynamics - Patients tend to return to RUCONEST quickly after trialing other treatments that do not control their crises effectively [37][38] Question: Timeline for getting patients on paid therapy in international markets - The company plans to submit pricing for reimbursement in Japan shortly, with launch timelines planned for summer [60][61] Question: Variants of uncertain significance (VUS) project timeline - New experiments are being planned, but timelines for results are not yet clear [76] Question: Inventory-related effects on RUCONEST sales - The company expects a higher inventory drawdown in Q1 due to market dynamics settling [78]

Financial Data and Key Metrics Changes - For the fourth quarter, net sales were $771 million, down 8% from $840 million in the same period last year [30] - Full year net sales were $2.96 billion, compared to $3.18 billion in the previous year [32] - Non-GAAP net income for the fourth quarter was $13 million, or $0.30 per diluted share, compared to $58 million, or $1.20 per diluted share in the previous year [32] - Full year non-GAAP net income was $116 million, or $2.61 per diluted share, down from $204 million, or $4.42 per diluted share in the previous year [35] Business Line Data and Key Metrics Changes - Key owned brands, including DKNY, Donna Karan, Karl Lagerfeld, and Vilebrequin, collectively delivered mid-single-digit growth, accounting for close to 60% of revenue, up from roughly 50% last year [9] - The wholesale segment's net sales were $737 million, down from $799 million in the previous year, while the retail segment's net sales increased to $63 million from $56 million [30] - Gross margins for the full year were 39.4%, down from 40.8% in the previous year, reflecting approximately $65 million of unmitigated impact from tariffs [34] Market Data and Key Metrics Changes - International sales accounted for just over 20% of fiscal 2026 net sales, indicating significant growth potential in global markets [10] - The brand Donna Karan saw approximately 40% growth, with strong performance in North America and a significant increase in online sales [11] - Karl Lagerfeld generated approximately $630 million in reported net sales, with a focus on expanding its global retail footprint [16] Company Strategy and Development Direction - The company is transitioning out of Calvin Klein and Tommy Hilfiger businesses, focusing on a strategic transformation of its portfolio [4] - Investments in infrastructure, technology, and talent are being made to support long-term growth [5] - The strategy emphasizes capturing the long-term potential of owned brands, driving direct-to-consumer sales, and expanding internationally [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their own brands and the ability to manage inventory levels effectively [50] - The company anticipates net sales of approximately $2.71 billion for fiscal 2027, reflecting a reduction due to the exit of Calvin Klein and Tommy Hilfiger businesses [37] - Non-GAAP net income for fiscal 2027 is expected to be between $88 million and $92 million, indicating a decrease from the previous year [38] Other Important Information - The company ended the year with over $400 million in cash and more than $900 million in total liquidity, after returning over $50 million to shareholders [36] - The company initiated its first-ever dividend program in December of the previous year [36] - The focus remains on enhancing omni-channel capabilities and returning the North American retail segment to profitability [24] Q&A Session Summary Question: Visibility on own brands for the year - Management noted that own brands grew high single digits last year, with inventory levels being controlled to support full-price business [49] Question: Update on Converse launch - Management indicated that they are building the Converse brand globally and are optimistic about its potential, contingent on Nike's support [55] Question: Prioritization of acquisitions versus licensing - Management stated that they are pursuing both acquisitions and licensing opportunities simultaneously, supported by a strong balance sheet [61] Question: Category expansion revenue contributors - Hospitality and DKNY were highlighted as key drivers for growth, with significant global licensing deals being signed [62]

Financial Data and Key Metrics Changes - Total revenues grew by 15% in Q4 2025 and by 27% for the full year, reaching EUR 376.1 million [2][25] - Operating profit for 2025 was $26 million, a significant improvement from a loss in 2024 [2] - Operating cash flow was $55 million in 2025, with cash position at year-end above 2024 levels [3][28] - Adjusted operating profit was EUR 36.4 million, compared to a loss of EUR 8.6 million in 2024 [28] Business Line Data and Key Metrics Changes - RUCONEST revenue grew 26% year-over-year and 9% in Q4 2025, with U.S. volume growth of 20% [4][9] - Joenja revenue increased by 29% year-over-year and 53% in Q4 2025, reaching $19.8 million globally [12][25] - Joenja's annual revenues exceeded EUR 50 million for the first time, triggering a EUR 5 million sales milestone payment [25] Market Data and Key Metrics Changes - Joenja's growth was fueled by new patient acceleration in the U.S. and increased demand in international markets, including the U.K. [4][14] - The number of identified APDS patients in the U.S. increased by 40 in 2025, more than double the increase in 2024 [14] Company Strategy and Development Direction - The company aims to maintain strong financial discipline while optimizing capital allocations to growth drivers [6][8] - Pharming is transitioning from a single asset company to a high-growth biotech with two commercial products and a late-stage pipeline [4] - The company expects 2026 revenue between EUR 405 million and EUR 425 million, representing 8%-13% growth [6][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth for RUCONEST and accelerating growth for Joenja, particularly in the U.S. pediatric market [7][30] - The company is focused on addressing FDA feedback regarding the pediatric label expansion for Joenja [22] - Management highlighted the importance of upcoming clinical data readouts as potential value inflection points [33] Other Important Information - The company completed the enrollment of two leniolisib phase 2 trials for lower prevalence PIDs, with data readouts expected in the second half of 2026 [7][19] - The company is committed to exploring M&A opportunities that are value-accretive and complementary to its mission [67] Q&A Session Summary Question: Joenja growth expectations from U.S. vs. international markets - Management expects approximately 70%-75% of Joenja's growth in 2026 to come from the U.S. market [41][43] Question: Dynamics of RUCONEST and patient returns - Patients tend to return to RUCONEST quickly after trialing new treatments that do not adequately control their crises [38] Question: Timeline for getting patients on paid therapy in international markets - The company plans to submit pricing for reimbursement in Japan shortly, with launch timelines planned for summer [60] Question: Variants of uncertain significance (VUS) and their potential reclassification - New experiments are planned to generate data needed for reclassification of VUS, but timelines are still uncertain [76] Question: Inventory-related effects on RUCONEST sales - The company anticipates a higher inventory drawdown in Q1 due to market dynamics settling, which is a common quarterly fluctuation [78]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated $581 million of marketplace Gross Order Value (GOV), down from $994 million in the prior year period, reflecting a 41.6% year-over-year decline [15] - Total marketplace orders decreased by 32% year-over-year, with the average order size dropping to $329 from $380 in Q4 2024 [15] - Q4 2025 revenues were $127 million, compared to $200 million in the prior year [16] - Adjusted EBITDA for Q4 2025 was $1 million, indicating a significant decline due to lower volume and negative operating leverage [16] - The company ended Q4 2025 with $103 million in cash and $390 million in debt, resulting in net debt of $287 million [17] Business Line Data and Key Metrics Changes - The marketplace take rate in Q4 2025 was 16.8%, slightly up from 16.6% in Q4 2024 [16] - The app's Gross Order Value (GOV) increased over 20% year-over-year through the first two months of 2026, with app share of GOV rising by more than 500 basis points since the launch of the enhanced app value proposition [11] Market Data and Key Metrics Changes - Industry volumes were down double digits in Q4 2025, primarily due to fewer concert onsales and a difficult comparison with the World Series [15] - The company expects Marketplace GOV for Q1 2026 to be in the range of $570 million to $620 million, consistent with Q4 2025 despite the latter being traditionally the strongest volume quarter [18] Company Strategy and Development Direction - The company is focusing on product innovation and efficiency, particularly through its app and web properties, to enhance the customer experience [8] - A significant cost reduction program has been implemented, increasing the target from $25 million to $60 million, which has been achieved [9] - The company aims to build long-term relationships with customers by emphasizing a rewarding ticketing experience and enhancing its app value proposition [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging Q4 2025 but noted emerging momentum in app performance and reaffirmed the 2026 outlook, expecting Marketplace GOV between $2.2 billion and $2.6 billion and adjusted EBITDA of $30 million to $40 million [12][19] - The company is optimistic about returning to growth in the second half of 2026, supported by a streamlined cost structure and improved operating leverage [20] Other Important Information - The company executed corporate simplification in Q4 2025, including the termination of its Tax Receivable Agreement and the collapse of its dual-class share structure, which is expected to improve transparency and generate financial benefits [10] Q&A Session Summary Question: Competitive dynamics and customer acquisition efficiency - Management noted a moderation in competitive intensity, particularly from StubHub, and emphasized the importance of maintaining unit economics while enhancing customer acquisition efficiency [23][24] Question: Impact of AI and ChatGPT on customer behavior - Management indicated that AI's impact on consumer behavior is still emerging, with current traffic through AI channels being a small percentage, but they believe it will grow significantly [26][28] Question: Industry trends and Ticketmaster's changes - Management observed that while Q4 was challenging, there has been a positive trend in concert onsales in Q1, and they expect stable to slight growth in the industry moving forward [34][35] Question: Customer acquisition strategy for the app - Management highlighted the importance of clearly communicating the app's value proposition and targeting existing customers with personalized messaging to drive traffic [42][43] Question: Regulatory impacts on industry dynamics - Management stated that they do not foresee any adverse effects from current regulatory discussions, but they will monitor developments closely [45] Question: Cash conversion and free cash flow generation - Management expects to be modestly cash generative in 2026, projecting that working capital will shift to being a source of cash as they return to growth [61] Question: Performance of special events like the World Cup - Management expressed confidence in capturing a share of GOV during intermittent sporting events, noting that these events tend to attract new customers [58][59]